Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for Windows
5 results
  • Focal necrotizing myopathy with 'dropped-head syndrome' induced by cobimetinib in metastatic melanoma. [Case Reports]
    Melanoma Res 2017; 27(5):511-515Gauci ML, Laly P, … Lebbé C
  • Therapeutic advances derived from targeted therapy and immune checkpoint inhibitors can improve melanoma prognosis. Since 2015, cobimetinib has been approved in combination with vemurafenib in the first-line treatment for BRAF-mutated melanoma. For NRAS-mutated melanomas, MEK inhibition seems to be a therapeutic target, and association with checkpoint inhibitor provides a further therapeutic pers…
  • Atypical severe immune-related adverse effects resulting from sequenced immunotherapy in melanoma. [Case Reports]
    Melanoma Res 2015; 25(2):178-9Danlos FX, Pagès C, … Lebbé C
  • We report unusual severe toxicity in three patients treated at our institution with sequenced immunotherapy for metastatic melanoma. These three patients illustrate the unusual potential toxicity of sequential administration of anti-programmed cell death 1 followed by ipilimumab, and the need for careful monitoring of these toxicities associated with sequential immunotherapies. Data from forthcom…
  • Report of two preventive medicine job market surveys. [Journal Article]
    Am J Prev Med 2001; 20(1):56-60Nitzkin JL, Falcao P, … Arraiano J
  • CONCLUSIONS: GPM board certification is of little or no value when competing for the vast majority of GPM-related jobs.The AAPHP recommends prompt coordinated action by national organizations representing GPM physicians to increase the number of job offerings preferring or requiring physicians with GPM board certification. A six-point action plan is proposed.
New Search